Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabThera in treatment-naïve non-bulky follicular NHL
NCT01392716Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 1997
- Primary completion
- Feb 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in follicular lymphoma (FL), sponsored by Roche. Primary endpoints: Overall objective complete response rate at Day 50 and Overall objective partial response rate at Day 50. Started Oct 1997; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01392716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392716.